Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) reported a fourth quarter loss of $1.03 per share and revenue of $7.2 million, as the messenger RNA medicines company

The company expects to initiate the 12-week Phase II ARCT-032 study in the first half of 2026, enrolling up to 20 participants and focusing on safety and early signs of clinical benefit. For ARCT-810, Type C regulatory meetings are scheduled for the first half of 2026 to align on pivotal trial designs for both adults and pediatric populations.

Arcturus Winds, featuring musicians from the Oregon Symphony, offer a chamber concert celebrating iconic space-themed music including favorites from “2001: A Space Odyssey,” Gustav Holst’s “The Planets,” James Shields’ “Anemos Arcturus,” and Samuel Barber’s “Summer Music.”

Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced its financial results for the fourth quarter and fiscal year 2025,